血哈普特蛋白水平对阿尔茨海默病的因果影响:一个双样本的孟德尔随机化研究
Yijia Lin1, Tingjun Hu1, Lizhen Cheng1
1Department of Geriatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal of Alzheimer's disease : JAD
|July 31, 2023
概括
较高的哈普托格洛宾 (Hp) 血水平增加了阿尔茨海默氏病 (AD) 的风险. 这项孟德尔随机化研究表明,hp可能是AD早期诊断和预防策略的目标.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物标志物 生物标志物
背景情况:
- 观察性研究表明,平分球蛋白 (Hp) 与阿尔茨海默氏病 (AD) 之间存在联系.
- 在HP和AD之间的因果关系仍然不清楚.
- 调查影响Hp水平的遗传因素对于了解AD的发病因子至关重要.
研究的目的:
- 确定血哈普托格洛宾 (Hp) 水平与阿尔茨海默氏病 (AD) 之间的因果关系.
- 使用双样本的门德尔随机化 (MR) 方法来进行可靠的因果推理.
- 探索Hp作为AD风险生物标志物的潜力.
主要方法:
- 采用了两个样本的门德尔随机化 (MR) 研究设计.
- 使用了全基因组关联研究 (GWAS) 的AD和Hp总结统计数据.
- 逆方差加权 (IVW) 和元分析是主要的统计方法.
主要成果:
- 基因确定较高的血hp水平与AD风险增加有关 (OR,1.05;95% CI,1.02-1.09).
- 对IVW估计的元分析证实了这种关联 (OR,1.03;95% CI,1.01-1.05).
- 没有观察到AD对HP水平的显著因果关系.
结论:
- 较高的血哈普托格洛宾 (Hp) 是阿尔茨海默病 (AD) 的因果风险因素.
- 这些发现支持了血Hp测试在早期AD诊断和预防方面的潜力.
- 进一步研究Hp在AD病变发生过程中的作用是有必要的.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
相关概念视频
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
